Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Roche has reported positive results from its Phase III REGENCY trial of Gazyva (obinutuzumab) for the treatment of lupus ...

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

The treatment procedures are required in the case of the severity of the condition. The patient then needs to go for a kidney ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech found success with a different B cell-killing ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, announces the appointment of Dr. Klaus Edvardsen as its new Chief Medical ...

AltaGas Ltd. ("AltaGas")  and Keyera Corp. ("Keyera")  are pleased to announce long-term commercial agreements that leverage each company's infrastructure to provide value-added services to customers ...

The sudden collapse of the Syrian government and President Bashar Assad’s flight to Russia in December marked a dramatic turning point for the country.